Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | BMC Research Notes

Fig. 6

From: Use of aminoglycoside 3′ adenyltransferase as a selection marker for Chlamydia trachomatis intron-mutagenesis and in vivo intron stability

Fig. 6

Western blot detection of IncA and RsbV1 in DFCT9, DFCT13, and DFCT16. Protein samples from cells infected in the absence of drug were run on SDS-PAGE, transferred to nitrocellulose, and probed with either anti-MOMP, anti-CT223, anti-IncA, or anti-RsbV1 antibodies. The anti-MOMP and anti-CT223 antibodies were used as controls to confirm the presence of bacteria and inclusion proteins, respectively, in each sample. Blots were then probed with HRP-conjugated secondary antibodies and visualized using a chemiluminescent substrate. Molecular weight markers (kDa) are shown to the left of each blot and the primary antibody used along with the predicted protein size are listed at the bottom of each blot. Contrast was adjusted (universally over the entire blot image) for the RsbV1 blot (to highlight band intensity). The (i) and (r) notations indicate the mutation(s) carried by the strain (incA and/or rsbV1)

Back to article page